124 related articles for article (PubMed ID: 27892725)
1. Investigational serine/threonine kinase inhibitors against prostate cancer metastases.
Festuccia C
Expert Opin Investig Drugs; 2017 Jan; 26(1):25-34. PubMed ID: 27892725
[TBL] [Abstract][Full Text] [Related]
2. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
4. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
Han CS; Patel R; Kim IY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
7. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
Batra A; Winquist E
Expert Opin Emerg Drugs; 2018 Dec; 23(4):271-282. PubMed ID: 30422005
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.
Polotti CF; Kim CJ; Chuchvara N; Polotti AB; Singer EA; Elsamra S
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1265-1273. PubMed ID: 29137489
[TBL] [Abstract][Full Text] [Related]
10. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
11. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
12. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
13. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
15. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
16. Reconsideration of progression to CRPC during androgen deprivation therapy.
Mizokami A; Namiki M
J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
[TBL] [Abstract][Full Text] [Related]
17. [Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2014 Dec; 72(12):2186-92. PubMed ID: 25518356
[TBL] [Abstract][Full Text] [Related]
18. Emerging serine-threonine kinase inhibitors for treating ovarian cancer.
Maoz A; Ciccone MA; Matsuzaki S; Coleman RL; Matsuo K
Expert Opin Emerg Drugs; 2019 Dec; 24(4):239-253. PubMed ID: 31755325
[No Abstract] [Full Text] [Related]
19. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
